XLi-356 | 914925-61-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯二氮卓类
• 英文名称: XLi-356
• 英文别名: 1,3-bis(8-ethyl-5,6-dihydro-5-methyl-6-oxo-4H-imidazo[1,5-a][1,4]benzodiazepine-3-carboxy)propyl diester；3-({12-Ethyl-8-methyl-9-oxo-2,4,8-triazatricyclo[8.4.0.0^{2,6}]tetradeca-1(14),3,5,10,12-pentaen-5-yl}carbonyloxy)propyl 12-ethyl-8-methyl-9-oxo-2,4,8-triazatricyclo[8.4.0.0^{2,6}]tetradeca-1(10),3,5,11,13-pentaene-5-carboxylate；3-(8-ethyl-5-methyl-6-oxo-4H-imidazo[1,5-a][1,4]benzodiazepine-3-carbonyl)oxypropyl 8-ethyl-5-methyl-6-oxo-4H-imidazo[1,5-a][1,4]benzodiazepine-3-carboxylate
• CAS: 914925-61-4
• 化学式: C₃₃H₃₄N₆O₆
• 分子量: 610.67
• InChiKey: AOQOJIJLIFNFFB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.6
• 重原子数：
  45
• 可旋转键数：
  10
• 环数：
  6.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  129
• 氢给体数：
  0
• 氢受体数：
  8

反应信息

• 作为产物：
  描述：

  XLi-093 在 palladium on activated charcoal 氢气 作用下， 以 乙醇 为溶剂， 反应 5.0h， 以99%的产率得到XLi-356
  参考文献：
  名称：

  GABAERGIC AGENTS TO TREAT MEMORY DEFICITS

  摘要：

  本发明提供了分子和方法，用于预防和/或治疗与记忆缺陷相关的疾病和/或提高认知能力。在一个首选实施例中，该发明包括化合物、盐和前药，用于预防和/或治疗这些疾病。

  公开号：

  US20060258643A1

文献信息

• GABAERGIC AGENTS TO TREAT MEMORY DEFICITS
  申请人：Cook M. James

  公开号：US20060258643A1

  公开（公告）日：2006-11-16

  The present invention provides molecules and methods for the prevention and/or treatment of memory deficit related conditions and/or enhancement of cognizance. In a preferred embodiment, the invention includes compounds, salts and prodrugs thereof for the prevention and/or treatment of these conditions.

  本发明提供了分子和方法，用于预防和/或治疗与记忆缺陷相关的疾病和/或提高认知能力。在一个首选实施例中，该发明包括化合物、盐和前药，用于预防和/或治疗这些疾病。
• Gabaergic Agents to Treat Memory Deficits
  申请人：Cook James M.

  公开号：US20100130479A1

  公开（公告）日：2010-05-27

  The present invention provides molecules and methods for the prevention and/or treatment of memory deficit related conditions and/or enhancement of cognition. In a preferred embodiment, the invention includes compounds, salts and prodrugs thereof for the prevention and/or treatment of these conditions.

  本发明提供了预防和/或治疗与记忆缺陷相关疾病和/或增强认知的分子和方法。在一个优选实施例中，本发明包括化合物、盐及其前药，用于预防和/或治疗这些疾病。
• US7595395B2
  申请人：——

  公开号：US7595395B2

  公开（公告）日：2009-09-29
• [EN] GABAERGIC AGENTS TO TREAT MEMORY DEFICITS<br/>[FR] AGENTS GABAERGIQUES UTILISES DANS LE TRAITEMENT DE TROUBLES DE LA MEMOIRE
  申请人：WISYS TECHNOLOGY FOUND INC

  公开号：WO2007018660A2

  公开（公告）日：2007-02-15

  [EN] The present invention provides molecules and methods for the prevention and/or treatment of memory deficit related conditions and/or enhancement of cognizance. In a preferred embodiment, the invention includes compounds, salts and prodrugs thereof for the prevention and/or treatment of these conditions.
  [FR] L'invention concerne des molécules et des méthodes de prévention et/ou de traitement d'états associés aux troubles de la mémoire et/ou à l'amélioration de la connaissance. Dans un mode de réalisation préféré, l'invention concerne des composés, des sels et des promédicaments de ceux-ci utilisés pour la prévention et/ou le traitement de ces états.
• A study of the structure–activity relationship of GABAA–benzodiazepine receptor bivalent ligands by conformational analysis with low temperature NMR and X-ray analysis
  作者：Dongmei Han、F. Holger Försterling、Xiaoyan Li、Jeffrey R. Deschamps、Damon Parrish、Hui Cao、Sundari Rallapalli、Terry Clayton、Yun Teng、Samarpan Majumder、Subramaniam Sankar、Bryan L. Roth、Werner Sieghart、Roman Furtmuller、James K. Rowlett、Michael R. Weed、James M. Cook

  DOI：10.1016/j.bmc.2008.08.072

  日期：2008.10

  The stable conformations of GABA(A)- benzodiazepine receptor bivalent ligands were determined by low temperature NMR spectroscopy and confirmed by single crystal X-ray analysis. The stable conformations in solution correlated well with those in the solid state. The linear conformation was important for these dimers to access the binding site and exhibit potent in vitro affinity and was illustrated for alpha 5 subtype selective ligands. Bivalent ligands with an oxygen-containing linker folded back upon themselves both in solution and the solid state. Dimers which are folded do not bind to Bz receptors. (C) 2008 Elsevier Ltd. All rights reserved.